17:35 , Nov 29, 2017 |  BioCentury  |  Emerging Company Profile

Gluten-free gut

PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...
20:41 , Jun 27, 2017 |  BC Extra  |  Financial News

Provention raises $28.4M in series A

Autoimmune and inflammatory disease prevention and interception play Provention Bio Inc. (Lebanon, N.J.) said it raised $28.4 million in a series A round from the Johnson & Johnson Innovation-JJDC Inc. arm of Johnson & Johnson...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Amgen, Celimmune deal

Amgen granted Celimmune exclusive, ex-Japan rights to develop and commercialize AMG 714. Celimmune is planning Phase II trials of the human mAb against IL-15 to treat diet non-responsive celiac disease and refractory celiac disease,...
01:42 , Mar 3, 2015 |  BC Extra  |  Company News

Celimmune licenses Amgen's celiac candidate

Amgen Inc. (NASDAQ:AMGN) granted Celimmune LLC (Bethesda, Md.) exclusive, worldwide rights outside of Japan to develop and commercialize AMG 714, a human mAb against IL-15. Amgen has an exclusive option to reacquire AMG 714 after...
07:00 , Jun 21, 2010 |  BioCentury  |  Finance

Business as usual - not!

If Genmab A/S were based in the U.S., activist investors would be demanding seats on the board and a say in the choice of a new CEO following last week's abrupt announcement that co-founder, President...
07:00 , Sep 17, 2009 |  BC Innovations  |  Targets & Mechanisms

Intercepting IL-15 in celiac disease

A group of American and Japanese researchers has shown that blocking IL-15 signaling decreased inflammation and tissue damage associated with celiac disease in mice.1 They now hope to acquire funding to test the strategy in...
07:00 , Jun 26, 2006 |  BC Week In Review  |  Clinical News

AMG 714: Additional Phase II data

Additional data from a placebo-controlled, double-blind Phase II trial in 180 patients showed that 29% of patients receiving 280 mg of AMG 714 achieved ACR50 and 14% achieved ACR70 at week 14. In patients who...
07:00 , May 22, 2006 |  BC Week In Review  |  Clinical News

AMG 714: Phase II data

Data from a double-blind, placebo controlled Phase II trial in 114 evaluable patients showed that AMG 714 missed the primary endpoint of a significantly higher proportion of patients achieving ACR20 at week 14. But more...
07:00 , Sep 12, 2005 |  BioCentury  |  Product Development

Late stage RA pipeline

Late stage RA pipeline Late stage RA pipeline Selected disease modifying compounds in Phase II and above for rheumatoid arthritis. (A) Did not meet the primary endpoint in the Phase II study, but Regeneron (REGN)...
07:00 , May 30, 2005 |  BioCentury  |  Finance

Ebb & Flow

Genentech (DNA) gained $3.6 billion of market cap last week on the heels of positive Phase III data for its Lucentis to treat age-related macular degeneration, far outstripping the market cap erased from the two...